For patients with nonvalvular atrial fibrillation, dabigatran 150 mg is comparable to warfarin in preventing ischemic stroke and also lowers risk of intracranial bleeding.
Rhythm control is not superior to rate control in patients with atrial fibrillation, and higher BMI appears to lower mortality risks.
For patients who have diabetes with atrial fibrillation, duration of diabetes may be a more important predictor of stroke than glycemic control.
Researchers analyzed results from 30 studies and found atrial fibrillation was associated with a higher risk of all-cause mortality in women, as well as stroke, cardiovascular mortality, cardiac events, and heart failure.
After adjustment for cardiovascular risk factors, diabetes was seen as independent risk factor for atrial fibrillation in a cross-sectional study in Shenyang, China.
Patients with atrial fibrillation who late gadolinium enhancement >35% had more recurrent atrial fibrillation, regardless of baseline persistence.
Patients with idiopathic dilated cardiomyopathy vs those with known heart disease had better outcomes in catheter ablation for atrial fibrillation.
For patients with nonvalvular atrial fibrillation, left atrial appendage closure may be the most cost-effective stroke prevention measure vs warfarin and NOACS.
Five cases of probable interaction, including severe renal impairment, between the anticoagulant acenocoumarol and levofloxacin were described in patients with atrial fibrillation.
Left atrial functional improvement independently predicated atrial fibrillation-free survival after cardiac resynchronization therapy.
